|
|
||||||||
Division of Nuclear Medicine, Department of Internal Medicine, University of Michigan Hospitals, Ann Arbor, Michigan
Correspondence: For reprints contact: B. Shapiro, MB, ChB, PhD, Div. of Nuclear Medicine, University of Michigan Hospitals, University Hospital B1G412/0028, 1500 E. Medical Center Dr., Ann Arbor, MI 48109/0028.
ABSTRACT
Iodine-131 MIBG scintigraphy may be used to determine the presence or absence of metastases to the appendicular skeleton in malignant pheochromocytoma and neuroblastoma. Normal bones show no uptake of [131I]MIBG and the joints are seen as photon-deficient areas surrounded by background muscle activity. Discrete concentrations of radioactivity in bone are often seen in patients with malignant pheochromocytoma and neuroblastoma. Bone marrow involvement in neuroblastoma may be indicated by diffuse uptake of [131I]MIBG or focal accumulation at the metaphyses. Uncommonly, bone involvement may not be displayed by the [131I]MIBG images. Since conventional bone scanning agents may also fail to detect these tumors, skeletal scintigraphy with both [131I]MIBG and [99mTc]MDP is necessary to reliably stage malignant pheochromocytoma and neuroblastoma.
This article has been cited by other articles:
![]() |
J. U. Kelly The Use of an Investigational Radiopharmaceutical in Neuroblastoma: A Nursing Perspective Journal of Pediatric Oncology Nursing, January 1, 1989; 6(4): 133 - 138. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |